Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cognetivity Neurosciences Ltd. (C:CGN)

Business Focus: Medical Software & Technology Services

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
Company Contact
Address: Suite 1430, 800 West Pender St.
VANCOUVER BC V6C 2V6
Tel: N/A
Website: https://www.cognetivity.com
IR: See website
Key People
Sina Habibi
Chief Executive Officer, Director
Thomas Roger Sawyer
Chief Financial Officer, Chief Operating Officer, Corporate Secretary, Director
Seyed Madhi Khaligh Razavi
Chief Scientific Officer
Christos Kalafatis
Chief Medical Officer, Director
   
Business Overview
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Company's ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
Financial Overview
For the nine months ended 31 October 2023, Cognetivity Neurosciences Ltd revenues increased from C$0K to C$54K. Net loss increased 25% to C$6.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Accretion expenses increase from C$116K to C$3.6M (expense), Other income decrease from C$209K (income) to C$0K.
Reporting Currency: Canadian Dollars
Enterprise value: $0.37M as of Oct 31, 2023
Annual revenue (TTM): $0.10M as of Oct 31, 2023
EBITDA (TTM): -$4.40M as of Oct 31, 2023
Net annual income (TTM): -$8.64M as of Oct 31, 2023
Free cash flow (TTM): -$3.88M as of Oct 31, 2023
Net Debt Last Fiscal Year: $1.35M as of Oct 31, 2023
Shares outstanding: 89,556,611 as of Oct 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization